Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Blood (2019) 134 (Supplement_1): 677.

https://doi.org/10.1182/blood-2019-125579

Published: 2019

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Laura L Hester, PhD MSc, Dina M Gifkins, PhD MPH, Kevin M Bellew, MS, MA, Jessica Vermeulen, MD PhD, Jordan M Schecter, MD, Frank J DeFalco, Brendan M Weiss, MD

Blood (2019) 134 (Supplement_1): 5517.

https://doi.org/10.1182/blood-2019-124250

Published: 2019

Journal Articles

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Galina Salogub, MD PhD, Jiri Mayer, MD, Frantisek Folber, MD PhD, Sebastian Grosicki, MD PhD, Aleksander B Skotnicki, MD PhD, Anna Prochwicz, MD, Alexander Myasnikov, MD, Alexander Gural, MD, Oliver Schoenborn-Kellenberger, MSc, Charlie Brindley, PhD, Stefan Knackmuss, PhD, Sylvia Schwarz, PhD, Sandra Schmich, Cassandra Choe-Juliak, MD MS, Andras Strassz, MD, Leila Alland, MD, Michael Doubek, MD PhD

Blood (2018) 132 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2018-99-118136

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Vikram Mathews, MD DM, Anu Korula, MD DM, Uday Kulkarni, MD, Saravanan Ganesan, MSc, Sachin David, MSc, Ansu Abu Alex, MSc, Nisham PN, MD DM, Aby Abraham, MD DM, Alok Srivastava, Kavitha M Lakshmi, MSc, Poonkuzhali Balasubramanian, MSc PhD, Biju George, MD DM

Blood (2016) 128 (22): 446.

https://doi.org/10.1182/blood.V128.22.446.446

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD

Blood (2016) 128 (22): 1856.

https://doi.org/10.1182/blood.V128.22.1856.1856

Published: 2016

Journal Articles

Pharmacovigilance of a Rituximab Biosimilar (Novex) in Argentina

Gustavo Milone, MD, Francisco Fernandez, Maria Ines Penna, Roberto Gomez

Blood (2016) 128 (22): 3568.

https://doi.org/10.1182/blood.V128.22.3568.3568

Published: 2016

Journal Articles

The Mayo Clinic Experience with Diagnosis and Treatment of Gardner-Diamond Syndrome

Meera Sridharan, MD, Uzma Ali, Rajiv K. Pruthi, MD, C Christopher Hook, MD, William L. Nichols, Jr., MD

Blood (2016) 128 (22): 3779.

https://doi.org/10.1182/blood.V128.22.3779.3779

Published: 2016

Journal Articles

Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis

Chatree Chai-Adisaksopha, MD, Davide Matino, Alfonso Iorio, MD PhD

Blood (2016) 128 (22): 1408.

https://doi.org/10.1182/blood.V128.22.1408.1408

Published: 2016

Journal Articles

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Diana M Byrnes, MD MPH, Christopher R Dermarkarian, BS, Ryan Kahn, BA, MHS, Deukwoo Kwon, PhD, Fernando Vargas, MD, Judith Hurley, MD, Justin M. Watts, MD, Jonathan H. Schatz, MD, Ronan T Swords, MD PhD FRCPI, FRCPath

Blood (2016) 128 (22): 5973.

https://doi.org/10.1182/blood.V128.22.5973.5973

Published: 2016

Journal Articles

Mexican Patient with Refractory Mycosis Fungoides Successfully Treated with Pralatrexate at Low Doses: Case Report

Jose R Lopez, Hematologist

Blood (2015) 126 (23): 5068.

https://doi.org/10.1182/blood.V126.23.5068.5068

Published: 2015

Journal Articles

Iliopsoas Hemorrhage in Pediatric Patients with Hemophilia, Experience from One Centre

Emine Türkkan, Didem Yalcin Atay, Suheyla Ocak, Gul Nihal Ozdemir, MD

Blood (2015) 126 (23): 4571.

https://doi.org/10.1182/blood.V126.23.4571.4571

Published: 2015

Journal Articles

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Giovanni Martinelli, MD, Hervé Dombret, Patrice Chevallier, MD PhD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Max S. Topp, MD, Adele K. Fielding, MB BS, PhD, Lulu Ren Sterling, PhD, Jonathan Benjamin, MD, Anthony Selwyn Stein, MD

Blood (2015) 126 (23): 679.

https://doi.org/10.1182/blood.V126.23.679.679

Published: 2015

Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD

Blood (2015) 126 (23): 680.

https://doi.org/10.1182/blood.V126.23.680.680

Published: 2015

Journal Articles

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Srdan Verstovsek, MD, Moshe Talpaz, MD, Ellen Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Tomonori Uno, PhD, Ruben A. Mesa

Blood (2015) 126 (23): 2800.

https://doi.org/10.1182/blood.V126.23.2800.2800

Published: 2015

Journal Articles

Clinicopathological Analysis of CNS Involvement in Multiple Myeloma

Tomiteru Togano, MDPhD, Sohtaro MINE, MD BPharm, BA, Akiyoshi Miwa, MD PhD, Shotaro Hagiwara

Blood (2015) 126 (23): 5326.

https://doi.org/10.1182/blood.V126.23.5326.5326

Published: 2015

Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)

Srdan Verstovsek, MD PhD, Moshe Talpaz, MD, Ellen K. Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady L Stein, MD, Uno Tomonori, PhD, Ruben Mesa, MD

Blood (2014) 124 (21): 1839.

https://doi.org/10.1182/blood.V124.21.1839.1839

Published: 2014

NARROW

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Pharmacovigilance of a Rituximab Biosimilar (Novex) in Argentina

The Mayo Clinic Experience with Diagnosis and Treatment of Gardner-Diamond Syndrome

Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis

Incidence of Neurological Complications Secondary to Intrathecal Chemotherapy Used As Either Prophylaxis or Treatment of Leptomeningeal Carcinomatosis

Mexican Patient with Refractory Mycosis Fungoides Successfully Treated with Pralatrexate at Low Doses: Case Report

Iliopsoas Hemorrhage in Pediatric Patients with Hemophilia, Experience from One Centre

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Clinicopathological Analysis of CNS Involvement in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only